More on NYSE

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Friends, Peers and Foes (?): ATNM, HGTXU, SEB, SONY, RBOT (more...)

Apr 22, 2026 07:01 AM Actinium reports ATNM-400 cancer therapy data at AACR meeting
Apr 22, 2026 07:01 AM Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Apr 22, 2026 07:01 AM Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer
Apr 6, 2026 07:30 AM Actinium Pharmaceuticals to present data on ATNM-400 and Actimab-A at AACR
Apr 6, 2026 07:30 AM Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Dec 23, 2025 06:50 AM Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026
Dec 12, 2025 08:45 AM Actinium presents breast cancer data for ATNM-400 at medical conference
Dec 12, 2025 08:45 AM Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,
Nov 3, 2025 08:30 AM Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
Oct 24, 2025 08:30 AM Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation
View All Articles

Entities mentioned with NYSE

View All Entities